# EDGAR Filing Document

**Accession Number:** 0001369290
**File Stem:** 0001193125-26-211988
**Filing Date:** 2026-5
**Character Count:** 124004
**Document Hash:** 9635e2816c7d86d4705ac1dd0a3ddb9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-211988.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-211988

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 66

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MYOMO, INC.
- **CENTRAL INDEX KEY:** 0001369290
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38109
- **FILM NUMBER:** 26953636

**BUSINESS ADDRESS:**
- **STREET 1:** 137 PORTLAND STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02114
- **BUSINESS PHONE:** 617-996-9058

**MAIL ADDRESS:**
- **STREET 1:** 137 PORTLAND STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MYOMO INC
- **DATE OF NAME CHANGE:** 20060718

?xml version='1.0' encoding='ASCII'? 10-Q

**4**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM** 10-Q

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended** **March 31,** 2026

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to .**

**Commission File Number** 001-38109

------

MYOMO, INC.

**(Exact name of Registrant as Specified in its Charter)**

------

---

| | |
|:---|:---|
| Delaware | 47-0944526 |
| **(State or Other Jurisdiction of** | **(I.R.S. Employer** |
| **Incorporation or Organization)** | **Identification No.)** |
| 45 Blue Sky Drive**,** Suite 101**,** Burlington**,** MA | 01803 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(**617**)** 996-9058

**Registrant's Telephone Number, Including Area Code** 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | MYO | NYSE American |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: ☒ No: ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company  | ☒ |
| Emerging growth company  | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

At May 1, 2026, the registrant has 38,638,653 shares of common stock, par value $0.0001 per share, outstanding.

------

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q includes forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Quarterly Report on Form 10-Q, including in "Risk Factors" and those contained in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on March 9, 2026 and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors include, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to achieve or obtain sufficient reimbursement from third-party payers for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our dependence upon external sources for the financing of our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to scale the business to return to positive cash flow from operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our revenue concentration with patients who have Medicare Part B insurance coverage;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our marketing and commercialization efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to effectively execute our business plan and scale up our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations as to our product development programs, including improving our existing products and developing new products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations as to our clinical research program and clinical results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to gain and maintain regulatory approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to compete and succeed in a highly competitive and evolving industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•other risks and uncertainties, including those listed under the captain "Risk Factors" in this Quarterly Report on Form 10-Q.

Although the forward-looking statements in this Quarterly Report on Form 10-Q and those contained in our Annual Report on the Form 10-K for the year ended December 31, 2025, are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law, to re-issue this Quarterly Report on Form 10-Q *or* otherwise make public statements updating our forward-looking statements.

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [**<u>PART I. FINANCIAL INFORMATION</u>**](#part_1_financial_information) |  |
| [**<u>Item 1. Financial Statements (interim periods unaudited)</u>**](#item_1_financial_statements) | 1 |
| [<u>Condensed Consolidated Balance Sheets at March 31, 2026 and December 31, 2025</u>](#condensed_balance_sheets) | 1 |
| [<u>Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025</u>](#condensed_consolidated_statements_operat) | 2 |
| [<u>Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2026 and 2025</u>](#condensed_consolidated_comprehensive_los) | 3 |
| [<u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended March 31, 2026 and 2025</u>](#condensed_statement_changes_in_stockhold) | 4 |
| [<u>Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025</u>](#condensed_statements_cash_flows_unaudite) | 5 |
| [<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>](#notes_to_condensed_unaudited_financial_s) | 6 |
| [<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 19 |
| [<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3_quantitative_qualitative_disclosu) | 25 |
| [<u>Item 4. Controls and Procedures</u>](#item_4_controls_procedures) | 25 |
| [**<u>PART II. OTHER INFORMATION</u>**](#part_ii_or_information) |  |
| [<u>Item 1. Legal Proceedings</u>](#item_1_legal_proceedings) | 27 |
| [<u>Item 1A. Risk Factors</u>](#item_1a_risk_factors) | 27 |
| [<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities</u>](#item_2_unregistered_sales_equity_securit) | 28 |
| [<u>Item 5. Other Information</u>](#item_5_other_information) | 26 |
| [<u>Item 6. Exhibits</u>](#item_6_exhibits) | 29 |
| [<u>Signatures</u>](#signatures) | 30 |

---

------

**Part 1. FINANCIAL INFORMATION**

**Item 1. Financial statements**

**MYOMO, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
|  | **2026** | **2025** |
|  | **(unaudited)** |  |
| **ASSETS** |  |  |
| **Current Assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $11396426 | $14132027 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term investments | 4299978 | 4261782 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 4824537 | 4096327 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 3548424 | 3123089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 1588453 | 1943860 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Assets** | 25657818 | 27557085 |
| Restricted Cash | 575000 | 575000 |
| **Operating lease assets with right of use, net** | 6499282 | 6679349 |
| **Equipment, net** | 2242811 | 2212901 |
| **Software development costs** | 1757402 | 1590864 |
| **Other assets** | 21374 | 21374 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Assets** | $36753687 | $38636573 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current Liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 7020809 | 5819767 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current operating lease liability | 594937 | 494662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes payable | 863236 | 813260 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 187498 | 218222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrant derivative liability | 718540 | 999418 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Current Liabilities** | 9385020 | 8345329 |
| Non-current operating lease liability | 7440778 | 7665622 |
| Long-term debt, net of discount of $2,733,243 | 10926208 | 11222155 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities** | 27752006 | 27233106 |
| **Commitments and Contingencies** |  |  |
| **Stockholders' Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock par value $0.0001 per share, 65,000,000 shares authorized; 38,566,277 and 38,471,383 shares issued as of March 31, <br>2026 and December 31, 2025, respectively; and 38,566,250 and 38,471,356 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 3856 | 3847 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 130527228 | 129929989 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 174882 | 164517 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (121697821) | (118688422) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, 27 shares at cost | (6464) | (6464) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Stockholders' Equity** | 9001681 | 11403467 |
| **Total Liabilities and Stockholders' Equity** | $36753687 | $38636573 |

---

*The accompanying notes are an integral part of the condensed unaudited consolidated financial statements.* 

------

**MYOMO, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **Revenue** | $10113288 | $9831814 |
| **Cost of revenue** | 3211682 | 3222184 |
| **Gross profit** | 6901606 | 6609630 |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 1623160 | 1790024 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, clinical and marketing | 4816759 | 4395804 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 3618739 | 3944056 |
|  | 10058658 | 10129884 |
| **Loss from operations** | (3157052) | (3520254) |
| **Other expense (income), net** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense (income), net | 504696 | (191991) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (839064) |  |
|  | (334368) | (191991) |
| **Loss before income taxes** | (2822684) | (3328263) |
| Income tax expense | 186715 | 136795 |
| **Net loss** | $(3009399) | $(3465058) |
| **Weighted average number of common shares outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | 42269133 | 41454472 |
| **Net loss per share attributable to common stockholders** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted | $(0.07) | $(0.08) |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

------

**MYOMO, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Net loss | $(3009399) | $(3465058) |
| Foreign currency translation adjustments | 13763 | (102452) |
| Unrealized (loss) income on short-term investments | (3398) | 313 |
| Other comprehensive income (loss) | 10365 | (102139) |
| Comprehensive loss | $(2999034) | $(3567197) |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

------

**MYOMO, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** | **For the Three Month Period Ending March 31, 2026 and 2025** |
|  | **Common stock** | **Common stock** | **Additional<br>Paid-in** | **Accumulated Comprehensive** | **Accumulated** | **Treasury Stock** | **Treasury Stock** | **Total<br>Stockholders'** |
|  | **Shares** | **Amount** | **Capital** | **(Loss) Income** | **Deficit** | **Shares** | **Amount** | **Equity** |
| Balance, January 1, 2026 | 38471383 | $3847 | $129929989 | $164517 | $(118688422) | 27 | $(6464) | $11403467 |
| Common stock issued upon vesting of restricted stock units | 94894 | 9 | (9) |  |  |  |  | (0) |
| Stock-based compensation |  |  | 597248 |  |  |  |  | 597248 |
| Unrealized loss on foreign currency adjustments |  |  |  | 10365 |  |  |  | 10365 |
| Net loss |  |  |  |  | (3009399) |  |  | (3009399) |
| Balance, March 31, 2026 | 38566277 | $3856 | $130527228 | $174882 | $(121697821) | 27 | $(6464) | $9001681 |
| Balance, January 1, 2025 | 34378297 | $3439 | $127846026 | $(14406) | $(103114538) | 27 | $(6464) | $24714057 |
| Common stock issued upon vesting of restricted stock units | 59031 | 7 | (7) |  |  |  |  |  |
| Common stock issued upon vesting of incentive stock options | 708 |  |  |  |  |  |  |  |
| Stock-based compensation |  |  | 540204 |  |  |  |  | 540204 |
| Unrealized loss on foreign currency adjustments |  |  |  | (102139) |  |  |  | (102139) |
| Net loss |  |  |  |  | (3465058) |  |  | (3465058) |
| Balance, March 31, 2025 | 34438036 | $3446 | $128386223 | $(116545) | $(106579596) | 27 | $(6464) | $21687064 |

---

*The accompanying notes are an integral part of the consolidated financial statements.*

------

**MYOMO, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)**

---

| | | |
|:---|:---|:---|
| **For the Three Months Ended March 31,** | **2026** | **2025** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(3009399) | $(3465058) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 291590 | 158442 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 597248 | 540204 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of discount on short-term investments | (41594) | (11747) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credit losses |  | 51643 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred offering costs | 262239 | 29039 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | 180067 | 288951 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (839064) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-cash changes | 27600 | (34171) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (691038) | (637054) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (447321) | (550772) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 350375 | (628186) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets |  | (70210) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 1207038 | 1440877 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (124570) | 164405 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (30724) | 46738 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 70217 |  |
| Net cash used in operating activities | (2197336) | (2676899) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of equipment | (327807) | (670688) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of software development costs | (166538) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of short-term investments |  | (1225410) |
| Net cash used in investing activities | (494345) | (1896098) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred debt origination costs |  | (36506) |
| Net cash used in financing activities |  | (36506) |
| Effect of foreign exchange rate changes on cash | (43920) | 30929 |
| Net change in cash and cash equivalents | (2735601) | (4578574) |
| Cash and cash equivalents beginning of year | 14707027 | 24747373 |
| Cash, cash equivalents and restricted cash end of year | $11971426 | $20168799 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for income taxes | $19200 | $330939 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest | $410474 | $111865 |
| Non-cash financing and investing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gain) loss from mark to market on short-term investments | $(3398) | $922 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

------

**MYOMO, INC.**

**NOTES TO CONDENSED CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS**

**Note 1 — Description of Business**

Myomo Inc. ("Myomo" or the Company") is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics ("O&P") providers around the world, the Veterans Health Administration, and distributors in Europe and Australia. The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Burlington, Massachusetts.

**Note 2 — Liquidity**

The Company incurred net losses of approximately $3,009,400, and $3,465,100 during the three months ended March 31, 2026 and 2025, respectively, and has an accumulated deficit of approximately $121,697,800 and $118,688,400 at March 31, 2026 and December 31, 2025, respectively. Cash used in operating activities was approximately $2,197,300 and $2,676,900 for the three months ended March 31, 2026 and 2025, respectively.

Based upon its current cash, cash equivalents, and short-term investments, as well as the future expected cash flows, the Company believes that its available cash, cash equivalents, and short-term investments will fund its operations for at least the next twelve months from the issuance date of these financial statements.

The Company has historically funded its operations through financing activities, including raising equity and debt. On November 4, 2025, the Company entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. as administrative agent and collateral agent and Avenue Venture Opportunities Fund II, L.P., as a lender, which provided the Company $17.5 million of committed capital, of which $12.5 million was funded at closing on November 4, 2025 (the "Closing Date"). The remaining $5.0 million becomes available at the Company's discretion between 12 and 18 months from the Closing Date, subject to maintaining compliance with covenants. The Company is paying interest only on the term loan for a period of 18 months from the Closing Date, which could be extended to 24 months if the Company borrowed under the second tranche. Proceeds from this loan were used to repay the outstanding borrowings under the credit facility with Silicon Valley Bank and to pay fees and expenses, with the remainder being used for general corporate purposes. These financing activities have enabled the Company to sustain its operations.

Management's operating plans are primarily focused on growing revenues from recurring sources, including expanding its MyoConnect program to generate referrals in rehab clinics and stroke centers around the country, continued growth in revenues in the O&P channel, as well as International operations, while reducing the cost of patient acquisition (measured as Cost per Pipeline Add) and minimizing the growth in fixed expenses. In addition, the Company believes that it has access to capital resources through possible public or private equity offerings, or other means.

**Note 3 — Summary of Significant Accounting Policies**

***Interim Financial Statements***

The accompanying unaudited condensed consolidated financial statements and notes are representations of the Company's management, who are responsible for their integrity and objectivity. These statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) that are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of March 31, 2026 and for the three months ended March 31, 2026 and 2025. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the operating results for the fiscal year ending December 31, 2026, or any other period. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2025 and 2024 and for the years then ended, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

***Basis of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary Myomo Europe GmbH. All significant intercompany balances and transactions are eliminated.

------

***Comprehensive Loss***

Comprehensive loss includes all changes in equity during a period, except those resulting from investments by stockholders and distributions to stockholders. The Company's comprehensive loss includes changes in foreign currency translation adjustments and unrealized gains and losses on short term investments.

***Use of Estimates***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company's estimates include assertion of collectability with payers as it relates to timing of revenue recognition and transaction pricing and the valuation of derivative liabilities.

***Cash, Cash Equivalents and Short-Term Investments***

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist principally of deposit accounts and money market accounts at March 31, 2026 and December 31, 2025.

The Company considers all investments with an original maturity of greater than three months but less than one year to be short-term investments. Short-term investments as of March 31, 2026 and December 31, 2025 consists of U.S. Treasury Bills and Commercial Paper, which are classified as available for sale, totaling approximately $4,300,000 and $4,261,800 as of March 31, 2026, and December 31, 2025, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchases and evaluates the classification at each balance sheet date. All of the Company's U.S. Treasury Bills mature within the subsequent twelve months from the date of purchase. Unrealized gains and losses on short-term investments are recorded to accumulated other comprehensive loss on the consolidated balance sheets and other gain (loss) on the consolidated statements of comprehensive loss. Once instruments with unrealized gains and losses become realized, they are reclassified from other comprehensive gains and losses to other income/expense.

The Company's cash balances as of March 31, 2026 and December 31, 2025 consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Cash and cash equivalents | $11396426 | $14132027 |
| Restricted cash | 575000 | 575000 |
| Total cash, cash equivalents, and restricted cash | $11971426 | $14707027 |

---

***Accounts Receivable and Allowance for Credit Losses***

The Company reports accounts receivable at invoiced amounts less an allowance for credit losses accounts. The Company evaluates its accounts receivable on a continuous basis and, if necessary, establishes an allowance for credit losses based on a number of factors, including current credit conditions and customer payment history. The Company does not require collateral or accrue interest on accounts receivable and credit terms are generally 30 days. At each of March 31, 2026, and December 31, 2025, the Company's balance for allowance for credit losses was approximately $102,700.

***Revenue Recognition***

The Company accounts for revenue under ASC 606, "Revenue from Contracts with Customers" and all the related amendments (Topic 606). Revenues under Topic 606 are required to be recognized either at a "point in time" or "over time," depending on the facts and circumstances of the arrangement and are evaluated using a five-step model. Generally, the Company recognizes revenue at a point in time.

The Company recognizes revenue after applying the following five steps:

1)Identification of the contract, or contracts, with a customer,

2)Identification of the performance obligations in the contract, including whether they are distinct within the context of the contract

3)Determination of the transaction price, including the constraint on variable consideration

4)Allocation of the transaction price to the performance obligations in the contract; and

5)Recognition of revenue when, or as, performance obligations are satisfied.

------

Revenue is recognized when control of these services is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.

The Company derives the majority of its revenue from direct billing. The Company also derives revenue from the sale of its products to orthotics and prosthetics or "O&P" providers in the United States and internationally and the Veterans' Administration (the "VA"). Under direct billing, the Company recognizes revenue when all of the following criteria are met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)The product has been delivered to the patient, including completion of initial instruction on its use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Collection is deemed probable and it has been determined that a significant reversal of the revenue to be recognized is not deemed probable when the uncertainty associated with the variable consideration is resolved; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)The amount to be collected is estimable using the "expected value" estimation techniques, or the "most likely amount" as defined in ASC 606.

The transaction price associated with the MyoPro for direct to patient revenue is generally determined by the insurance payer. For patients with Medicare Part B, the transaction price is based on the published fees for our billing codes L8701 and L8702. Medicare pays 80% of the published fees, less certain deductions. If a patient has insurance that supplements Medicare Part B with a payer for which sufficient payment history exists or is a non-employer-based plan, the Company estimates the transaction price based on receiving the remaining 20% of the Medicare allowable. For patients that do not carry Medicare Part B, the transaction price is based on either a contracted price or is estimated using the expected value method based on previous collection history with the payer. For U.S. and International O&P providers and the VA, the transaction price is an amount agreed in advance between the parties and evidenced by a purchase order or Myomo order form.

For revenue derived from patients under Medicare Part B, the Company recognizes revenue once it has obtained sufficient medical documentation to demonstrate medical necessity and when control of the device has passed to the patient. Patients with Medicare Part B insurance coverage represented 51% and 59% of revenue for the three months ended March 31, 2026 and 2025, respectively. With respect to patients with certain Medicare Advantage insurance plans, the Company will recognize revenue when it receives a pre-authorization from the insurance company and control passes to the patient upon delivery of the device in an amount that reflects the consideration the Company expects to receive in exchange for the device. These payers represented approximately 18% and 16% of revenue in the three months ended March 31, 2026 and 2025, respectively.

Depending on the timing of product deliveries to customers, which is when cost of revenue must be recorded, and when the Company meets the criteria to record revenue, there may be fluctuations in gross margin. During the three months ended March 31, 2026 and 2025, the Company recognized revenue of approximately $811,800 and $836,100, respectively, from third-party payers for which costs related to the completion of the Company's performance obligations were not recorded in the current period.

For revenues derived from O&P providers and the VA, the Company recognizes revenue when control passes to the customer in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenues may be recognized upon shipment or upon delivery, depending on the terms of the arrangement, provided that persuasive evidence of an arrangement exists, there are no uncertainties regarding customer acceptance and collectability is deemed probable.

The Company has elected to record taxes collected from customers on a net basis and does not include tax amounts in revenue or cost of revenue.

***Software Development***

The Company accounts for costs incurred to develop internal-use software in accordance with ASC 350-40, Internal-Use Software. Costs incurred during the preliminary project stage and post-implementation stage are expensed as incurred. Once an application has reached the development stage and it is probable that the software will be completed and used for its intended purpose, internal and external direct costs incurred to develop the software are capitalized. Capitalized costs consist of third-party costs directly attributable to the development of the software. Capitalized Software Development Costs are amortized on a straight-line basis over the estimated useful life of the software. The Company evaluates capitalized internal-use software for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Costs related to internal-use software capitalized during the period were approximately $166,500 in the three months ended March, 31, 2026 and $1,590,900 in the year ended December 31, 2025.

***Contract Balances*** 

The timing of revenue recognition may differ from the timing of payment by customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the provision of the related

------

services, the Company records deferred revenue until the performance obligations are satisfied. The Company had deferred revenue of approximately $187,500 and $218,200 as of March 31, 2026 and December 31, 2025, respectively.

***Disaggregated Revenue from Contracts with Customers***

The following table presents revenue by major source:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** |
|  | **2026** | **2025** |
| Direct to patient | $7168338 | $7807777 |
| Clinical/Medical providers | 2944950 | 2024037 |
| Total revenue from contracts with customers | $10113288 | $9831814 |

---

***Geographic Data***

The Company generated 80% of its total revenue from the United States and 20% from Germany for the three months ended March 31, 2026. The Company generated 87% of its total revenue from the United States, 13% from Germany, and 1% from other international locations, for the three months ended March 31, 2025.

***Cost of Revenue***

In conjunction with the adoption of ASC 606, there are certain cases in which the Company will expense costs when incurred as required by ASC 340-40-25. In certain cases, the Company provides the MyoPro device directly to patients, pending reimbursement from third-party payers, after which revenue is recognized. For the three months ended March 31, 2026 and 2025, the Company recorded cost of goods sold of approximately $59,600 and $32,400, respectively, without corresponding revenue. Direct billing fees paid to O&P providers for services they provide in conjunction with patient evaluations are expensed as incurred as required by ASC 340-40-25. These costs are recorded as sales and marketing expense. Internal costs incurred and fees paid to O&P providers to measure, fit and deliver the device to patients are expensed to cost of revenue.

***Advertising***

The Company charges the costs of advertising to operating expenses as incurred. Advertising expense amounted to approximately $1,843,700 and $1,609,700 during the three months ended March 31, 2026 and 2025, respectively.

***Foreign Currency Translation***

The functional currency of the Company's foreign subsidiary, Myomo Europe GmbH, is the Euro. Foreign exchange translation gains and losses from the Euro to U.S. dollars are included in other comprehensive gain. The Company recorded a comprehensive income (loss) of approximately $13,800 and $102,500 during the three months ended March 31, 2026 and 2025, respectively, which are included in accumulated other comprehensive income in the condensed consolidated balance sheet. Transaction and translation foreign exchange gains and losses from a foreign currency to the functional currency are included in cost of revenue in the condensed consolidated statements of operations. Such amounts were immaterial for the three months ended March 31, 2026 and 2025, respectively. The balance sheet is translated using the spot rate on the day of reporting and the statement of operations is translated monthly using the average rate for the month.

***Net Loss per Share***

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding, plus potentially dilutive common shares. Restricted stock, restricted stock units, stock options and warrants are excluded from the diluted net loss per share calculation when their impact is antidilutive. The Company reported a net loss for the three months ended March 31, 2026 and 2025, and as a result, all potentially dilutive common shares are considered antidilutive for these periods.

Potential dilutive common shares issuable consist of the following at:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Stock options | 20953 | 22383 |
| Restricted stock units | 1697371 | 1190511 |
| Other warrants | 1367187 |  |
| Total | 3085511 | 1212894 |

---

------

Due to their nominal exercise price of $0.0001 per share, a total of 3,763,258 and 7,061,519 outstanding pre-funded warrants as of March 31, 2026 and 2025, respectively, are considered common stock equivalents and are included in weighted average shares outstanding in the accompanying condensed consolidated statements of operations as of the respective closing dates of the Company's public equity offerings.

***Recently Adopted Accounting Standards***

In October 2023, the FASB issued ASU 2023-06, "Disclosure Improvements, Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative", that adds 14 of the 27 identified disclosure or presentation requirements to the Codification, each amendment in the ASU will only become effective if the SEC removes the related disclosure or presentation from its existing regulations by

June 30, 2027. The Company currently complies with these disclosure requirements as applicable under Regulation S-X or Regulation S-K and will adopt these new standards depending on timing of when they become effective, which is not expected to have a material impact on its financial position and results of operations.

In November 2024, the FASB issued ASU 2024-03 "Disaggregation of Income Statement Expenses (Subtopic 220-40) Disaggregation of Income Statement Expenses." The update requires public business entities to provide enhanced disclosures in the note to the financial statements about the nature of expenses included in income statement captions. The new disclosures will require entities to disaggregate relevant expense captions and present these in a tabular format. At a minimum, the disaggregation must include amounts for; purchases of inventory, employee compensation, depreciation, and intangible asset amortization. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. Early adoption is permitted, which is not expected to have a material impact on the Company's financial position and results of operations.

**Note 4 — Inventories**

Inventories consist of the following at:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Finished goods | $857762 | $930837 |
| Work in process | 39542 | 28204 |
| Parts and subassemblies | 2651120 | 2164048 |
| Inventories | $3548424 | $3123089 |

---

**Note 5 — Fair Value of Financial Instruments**

The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, "Fair Value Measurement" ("ASC 820"), which defines fair value, establishes a framework for measuring fair value, and establishes disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 1 — Quoted prices available in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 2 — Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

------

The carrying amounts of the Company's financial instruments such as cash and cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these instruments. Cash equivalents consist of a money market fund that limits its investments to only short-term U.S. Treasury securities and repurchase agreements related to these securities.

The Company considers all investments with an original maturity of greater than three months to be short-term investments. Short-term investments are carried on the consolidated balance sheets at fair value. Short-term investments as of March 31, 2026 and December 31, 2025 consisted of U.S. Treasury Bills, which are classified as available for sale, agency bonds and commercial paper totaling approximately $4,300,000 and $4,261,800, respectively. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at the date of purchase. Unrealized gains and losses on short-term investments are recorded to accumulated other comprehensive income on the condensed consolidated balance sheets and other comprehensive income (loss) on the condensed consolidated statements of comprehensive loss. Once unrealized gains and losses become realized, they are reclassified from other comprehensive gains and losses to other (income) expense.

Cash equivalents and short-term investments measured at fair value at March 31, 2026 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **In Active<br>Markets for<br>Identical Assets<br>or Liabilities<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** | **Total** |
| Money market funds | $8361840 | $— | $— | $8361840 |
| Short-term investments |  | 4299978 |  | 4299978 |
| Warrant liability |  |  | 718540 |  |
| Compound derivative liability |  |  | 1091743 |  |

---

Cash equivalents and short-term investments measured at fair value on a recurring basis at December 31, 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **In Active<br>Markets for<br>Identical Assets<br>or Liabilities<br>(Level 1)** | **Significant<br>Other<br>Observable<br>Inputs<br>(Level 2)** | **Significant<br>Unobservable<br>Inputs<br>(Level 3)** | **Total** |
| Money market funds | $10234433 | $— | $— | $10234433 |
| Commercial paper |  | 1645442 |  | 1645442 |
| Short-term investments |  | 4261782 |  | 4261782 |
| Warrant liability |  |  | 999418 |  |
| Compound derivative liability |  |  | 1649929 |  |

---

The following table presents the fair value reconciliation of Level 3 liabilities measured at fair value during the periods ending March 31, 2026 and December 31, 2025, respectively:

---

| | | | |
|:---|:---|:---|:---|
|  | **Warrant Liability** | **Compound<br>Derivative Liability** | **Total** |
| Balance – December 31, 2025 | $999418 | $1649929 | $2649347 |
| Change in fair value of derivative liabilities | (280878) | (558186) | (839064) |
| Balance – March 31, 2026 | $718540 | $1091743 | $1810283 |

---

Valuation assumptions utilized in the valuation of Level 3 liability under the Monte Carlo model for warrants at March 31, 2026 and December 31, 2025 were as follows:

------

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| Risk-free interest rate | 3.86% | 3.68% |
| Stock price | $0.676 | $0.91 |
| Initial exercise price - Warrants | $0.96 | $0.96 |
| Volatility | 96.43% | 95.21% |
| Dividend yield | 0.0% | 0.0% |
| Remaining term - Warrants | 4.60 | 4.84 |

---

The expected stock price volatility for the Company's warrant liability was based on the Company's historical volatility. Risk free interest rates were obtained from U.S. Treasury rates for the applicable periods. The expected term used is the contractual life of the instrument being valued. The company has historically not paid any dividends and does not have any intention to do so in the future.

The valuation assumptions for the compound derivative liability under the Monte Carlo model are based on determining the fair value of the debt, excluding warrants with and without the derivative features, which include the conversion option for a portion of the debt, the default interest provision and acceleration of the debt upon an event of default. Key inputs for the valuation of the debt include a credit spread of 22.39% and an issuance date annualized risk-free rate of 3.72%.

---

| | | |
|:---|:---|:---|
|  | **<u>March 31, 2026</u>** | **<u>December 31, 2025</u>** |
| Remaining term - loan | 3.17 | 3.42 |
| Credit spread | 22.39% | 22.39% |
| Implied debt yield | 26.11% | 26.11% |
| Annualized risk-free rate | 3.72% | 3.72% |

---

**Note** 6 - **Accounts Payable and Other Accrued Expenses**

Accounts Payable and Other Accrued Expenses consist of the following at:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Trade payables | $1812861 | $1101228 |
| Accrued compensation and benefits | 2851217 | 1952578 |
| Accrued professional services | 65600 | 85696 |
| Warranty reserve | 163140 | 148296 |
| Customer deposits | 1938883 | 1930339 |
| Accrued insurance |  | 191258 |
| Other | 189108 | 410372 |
|  | $7020809 | $5819767 |

---

**Note 7 — Debt**

On November 4, 2025 (the "Closing Date"), the Company entered into a Loan and Security Agreement (the "Loan and Security Agreement"), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the "Agent") and Avenue Venture Opportunities Fund II, L.P., as a lender ("Avenue", or the "Lender"). Also on November 4, 2025, the Company entered into a Supplement to the Loan and Security Agreement (the "Supplement" and together with the Loan and Security Agreement, the "Loan Agreement") with the Agent and the Lender.

The Loan Agreement provides for committed term loans in an aggregate principal amount of up to $17.5 million with (a) $12.5 million funded on the Closing Date ("Tranche 1") and (b) up to $5.0 million to be funded at any time at the discretion of the Company between November 4, 2026 and May 4, 2027, so long as no default or event of default has occurred and is continuing. Upon the mutual agreement of the Company and the Lender, the Lender may make additional term loans of up to an additional $10.0 million (the "Discretionary Tranche 3" and collectively

------

with Tranche 1 and Tranche 2, the "Loans"), to be funded between January 1, 2027 and December 31, 2027, as the Company and the Lenders may mutually agree. The Loans bear interest at an annual rate equal to the sum of 4.75% and the prime rate as reported in The Wall Street Journal, subject to a prime floor equal to The Wall Street Journal prime rate on Closing Date. The maturity date of the Loans is June 1, 2029 (the "Maturity Date").

The Company is making interest only payments on the Loans until the 18-month anniversary of the Closing Date, subject to a 6-month extension if the funding of Tranche 2 has occurred. The Loan principal is repayable in equal monthly installments from the end of interest only period to the Maturity Date.

The Company may, at its option at any time, prepay the Loans in their entirety by paying the then outstanding principal balance and all accrued and unpaid interest on the Loans, subject to a prepayment fee equal to (i) 3.0% of the principal amount outstanding if the prepayment occurs on or prior to the first anniversary following the Closing Date, (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first anniversary following the Closing Date, but on or prior to the second anniversary following the Closing Date, and (iii) 1.0% of the principal amount outstanding if the prepayment occurs after the second anniversary following the Closing Date. A final payment fee of 3.25% of the principal amount of the Loans (subject to certain reductions), is also due upon the Maturity Date or earlier date of prepayment of the Loans. The Loan is secured by a lien upon and security interest in all of the Company's assets, including intellectual property, in which the Agent is granted senior secured lien.

Pursuant to the Loan Agreement, the Company is subject to certain financial covenants requiring the Company to (i) maintain at all times $2.5 million in unrestricted cash, (ii) achieve at least 75% of its trailing three-month projected revenue and (iii) achieve cash burn for the trailing six months of no more than the greater of 150% of its projected cash burn, or $2.0 million.

Pursuant to the Loan Agreement, the Lender also has the right to convert up to $3.0 million of the outstanding principal of Tranche 1 and up to $1.0 million of the outstanding principal of Tranche 2 into shares of Company common stock (the "Conversion Securities") at a price per share equal to 120% of the exercise price of the warrant at any time while the Loans are outstanding, subject to certain terms and conditions, including ownership limitations. The conversion feature and other terms in the Loan Agreement were bifurcated from the debt at inception and are being recorded as a compound derivative liability which is being recorded at fair value. At inception, the Company recorded a derivative liability of approximately $1,514,400. At March 31, 2026, the derivative liability was determined to have a fair value of approximately $1,091,700. A gain of approximately $558,200 was recorded to change in fair value of derivative liability in other income, net for the three months ended March 31, 2026. At December 31, 2025, the derivative liability was determined to have a fair value of approximately $1,649,900.

The Company recorded approximately $821,100 in debt issuance costs during the year ended December 31, 2025 in conjunction with entering into the Loan Agreement, which includes a commitment fee as well as banking and legal fees. The Company capitalized the portion of debt issuance costs allocated to the debt and is amortizing them into interest expense using the interest rate method, which approximates straight-line amortization over the term of the Loan Agreement. The debt issuance costs that were allocated to the warrant and the compound derivative liability of approximately $151,200 were charged to interest expense at inception of the Loan Agreement. As of March 31, 2026, the balance of debt issuance costs was approximately $590,200, which is included in debt discount on the consolidated balance sheet. The Company amortized $47,800 of debt issuance costs, including those amortized from the issuance of the credit facility, to interest expense during the three months ended March 31, 2026. As of December 31, 2025, the balance of debt issuance costs was approximately $638,000, which is included in debt discount on the consolidated balance sheet. The Company amortized $226,300 of debt issuance costs, including those amortized from the issuance of the credit facility, to interest expense during the year ended December 31, 2025.

Concurrent with the closing of the Loan Agreement, the Company repaid $4,000,000 to Silicon Valley Bank, representing all amounts outstanding under its credit facility. In addition, the Company paid pre-payment and other fees and wrote-off unamortized debt issuance costs associated with terminating the credit facility, which resulted in the recording of approximately $186,400 to interest expense during the year ended December 31, 2025.

Including the aforementioned amounts, the Company recorded interest expense of approximately $632,100 and $37,100 under its debt facilities during the three months ended March 31, 2026 and 2025, respectively.

---

| | | |
|:---|:---|:---|
|  | **<u>March 31, 2026</u>** | **<u>December 31, 2025</u>** |
| Long-term debt | $12567708 | $12527083 |
| Compound derivative | 1091743 | 1649929 |
| Discount | (2733243) | (2954857) |
| Long term debt, net of discount | $10926208 | $11222155 |

---

------

**Note 8 — Common Stock and Warrants**

Pursuant to an amended and restated certificate of incorporation, the Company is authorized to issue up to 75,000,000 shares of stock, consisting of 65,000,000 shares of common stock, par value $0.0001, and 10,000,000 shares of undesignated Preferred Stock, par value of $0.000.

In conjunction with entering into the Loan Agreement (See Note 7), the Company issued to Avenue a warrant to purchase up to $1,312,500 worth of shares of the Company's common stock (the "Warrant"). The warrant expires on November 4, 2030 and has an exercise price per share equal to the lesser of (i) $0.96 and (ii) the price per share of the Company's next bona fide round of equity financing before June 30, 2026 for the purposes of raising capital.

In addition, upon a change of control, Avenue is entitled to receive the shares of common stock underlying the Warrant without payment of the exercise price. Avenue may exercise the warrant at any time, or from time to time up to and including the Expiration Date, by making a cash payment equal to the exercise price multiplied by the quantity of shares. Avenue may also exercise the warrant on a cashless basis by receiving a net number of shares calculated pursuant to the formula set forth in the warrant. The warrant is subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits.

The Company is accounting for the warrant as a derivative liability, which is recorded at fair value. At inception, the Company recorded a derivative liability of approximately $918,000. As of March 31, 2026, the derivative liability was determined to have a fair value of approximately $718,500, and the Company recorded a gain from the change in fair value of derivative liabilities in other expense (income) of approximately $280,900, At December 31, 2025, the derivative liability was determined to have a fair value of approximately $999,000.

As of March 31, 2026, 3,763,258 pre-funded warrants remain exercisable. Each pre-funded warrant is exercisable for one share of the Company's common stock at a nominal exercise price of $0.0001 per share. No pre-funded warrants were exercised during the three months ended March 31, 2026 and 2025, respectively.

There were no shares of common stock issued through the exercise of stock options during the three months ended March 31, 2026 and 708 during the three months ended March 31, 2025.

During the three months ended March 31, 2026 and 2025, 94,894 and 59,031 restricted stock units vested, respectively.

**Note 9 — Stock Award Plans and Stock-Based Compensation**

As of March 31, 2026, there were 2,013,091 shares available for issuance under the Myomo, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan"). On January 1 of each year, the number of shares of common stock reserved and available for issuance under the 2018 Plan will cumulatively increase by 4% of the number shares of common stock outstanding on the immediately preceding December 31 or such lesser number of shares of common stock determined by management in consultation with members of the Board of Directors, including the compensation committee of the Board of Directors. On January 1, 2026, 1,538,854 shares were added to the share reserve under the 2018 Plan.

Recipients of awards of restricted stock units typically sell shares in the open market to cover their individual tax liabilities and remit the proceeds to the Company, which offsets withholding taxes paid by the Company. In certain circumstances, stock awards may be net share settled upon vesting to cover the required employee statutory withholding taxes and the remaining amount is converted into shares based upon their share-value on the date the award vests. In such instances, these payments of employee withholding taxes are presented in the statements of cash flows as a financing activity. There were no stock awards that were net share settled during the three months ended March 31, 2026 and 2025, respectively.

***Share-Based Compensation Expense***

The Company accounts for stock awards to employees and non-employees based upon the fair value of the award on the date of grant. The fair value of that award is then ratably recognized as expense over the period during which the recipient is required to provide services in exchange for that award.

------

The Company attributes the value of stock-based compensation to operations on the straight-line method such that the expense associated with awards is evenly recognized over the vesting period.

The Company recognized stock-based compensation expense related to the issuance of stock option awards and restricted stock units to employees, non-employees and directors in the statements of operations as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Cost of goods sold | $47113 | $41718 |
| Research and development | 62359 | 78155 |
| Selling, clinical, and marketing | 112493 | 80239 |
| General and administrative | 375283 | 340092 |
| Total | $597248 | $540204 |

---

As of March 31, 2026, there was no unrecognized compensation cost related to unvested stock options.

As of March 31, 2026, there was approximately $3,396,400 of unrecognized compensation expense related to unvested restricted stock units that is expected to be recognized over a weighted-average period of 1.89 years.

**Note 10 — Commitments and Contingencies**

**Litigation**

The Company may be involved from time to time in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no material claims, assessments or litigation against the Company as of March 31, 2026.

**Operating Leases**

The Company had a lease agreement for its corporate headquarters in Boston, Massachusetts, which expired in January 2025 and had a lease agreement for office space in Fort Worth, TX. which expired December 2025. In August 2024, the Company entered into a lease agreement for a new corporate headquarters and manufacturing facility in Burlington, Massachusetts. The Company began relocating operations in December 2024 and completed the move in January 2025. The term of the lease is 88 months following the rent commencement date, which was May 11, 2025. The Company has the option to extend the new lease for an additional five years, subject to certain conditions being satisfied. Under the new lease, the Company provided a security deposit to the landlord in the form of a letter of credit for $375,000. The Company has collateralized the letter of credit with cash in a separate bank account, which is accounted for as long-term restricted cash on the condensed consolidated balance sheet. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets. The Company recognizes rent expense on a straight-line basis over the lease term.

As of March 31, 2026, operating lease assets were approximately $6,499,300 and operating lease liabilities were approximately $8,035,700. The maturity of the Company's operating lease liabilities as of March 31, 2026, were as follows:

---

| | |
|:---|:---|
|  | **March 31, 2026** |
| 2026 | $909169 |
| 2027 | 1525416 |
| 2028 | 1592125 |
| 2029 | 1650479 |
| Thereafter | 4872994 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total future minimum lease payments | 10550183 |
| Less imputed interest | 2514468 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating lease liabilities | $8035715 |
| **Included in the condensed consolidated balance sheet:** |  |
| Current operating lease liabilities | $594937 |
| Non-current operating lease liabilities | 7440778 |
| Total operating lease liabilities | $8035715 |

---

------

For the three months ended March 31, 2026 and 2025, the total lease cost is comprised of the following amounts:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** |
|  | **2026** | **2025** |
| Operating lease expense | $344247 | $401809 |
| Short-term lease expense | 612 | 1722 |
| Total lease expense | $344859 | $403531 |

---

The following summarizes additional information related to operating leases:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| Weighted-average remaining lease term (in years) | 6.5 | 6.7 |
| Weighted-average discount rate | 8.5% | 8.5% |

---

**Insurance Obligations**

The Company finances the insurance policies of its directors and officers, which requires the Company to make a down payment, followed by equal payments over a defined term. The Company then entered into a financing arrangement covering the twelve-month period ending in June 2025. Under this financing arrangement, the Company made a down payment of approximately $39,000 during the three months ended June 30, 2024, and made nine equal monthly payments of approximately $39,000, ending in March 2025. The Company then entered into a new financing arrangement for its 2025-2026 insurance policies covering the twelve month period ending in June 2026. The Company made a down payment of $68,400 during the three months ended June 30, 2025 and is making 10 equal monthly payments of approximately $40,300, starting in July 2025.

The Company also finances its property and casualty insurance policies, which require the Company to make a down payment, followed by equal payments over a defined term. During the three months ended September 30, 2025, the Company entered in a new financing arrangement for its 2025-2026 policy covering the twelve months ended July 2026. The Company made a down payment of $55,400 and is making 8 equal payments of approximately $24,300, starting in August 2025.

Changes in the Company's supplier finance obligations were as follows and included in prepaid and accrued expenses on the consolidated balance sheet statement:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Opening January 1 | $284201 | $181256 |
| Payments |  |  |
| Expensed | (187378) | (98508) |
| Ending | $96823 | $82748 |

---

No assets are pledged as security under this arrangement.

------

**Note 11 — Segment Reporting and Major Customers**

*Segment Reporting*

ACS 280, "Segment Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about products, business segments, and major customers in financial statements. The Company conducts its business in one operating segment, and sells products in one family, which are versions of the MyoPro. While the Company has several sales channels and operates in different geographies, the Chief Executive Officer, who is the Company's chief operating decision-maker, and is responsible for allocating resources and assessing the performance of the Company, manages the Company's business on a consolidated basis, focusing on revenue, gross margin, certain operating expenses, loss from operations, other expenses (income), Income Tax, and Net loss. The Chief Executive Officer reviews the consolidated balance sheet with relation to consolidated Assets. The Chief Executive Officer does not review any additional or more disaggregated level.

---

| | | |
|:---|:---|:---|
| **<u>For the three months ended March 31,</u>** | **2026** | **2025** |
| **Revenue** | $10113288 | $9831814 |
|  | 10113288 | 9831814 |
| **Cost of revenue** | 3211682 | 3222184 |
| **Gross profit** | 6901606 | 6609630 |
| **Gross margin** | 68.2% | 67.2% |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payroll and benefits expense | 7215761 | 6777535 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising | 1843689 | 1609688 |
| &nbsp;&nbsp;&nbsp;&nbsp;All other segment operating expenses | 2390306 | 3289233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payroll and benefits expense in cost of revenue | (1391098) | (1536572) |
|  | 10058658 | 10139884 |
| **Loss from operations** | $(3157052) | $(3530254) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense (income), net | 504696 | (191991) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (839064) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 186715 | 136795 |
| **Net Loss** | $(3009399) | $(3475058) |

---

**Major Customers**

For the three months ended March 31, 2026 and 2025, there were no customers which accounted for more than 10% of revenues. For the three months ended March 31, 2026 and 2025, the Centers for Medicare and Medicaid Services ("CMS") represented 51% and 59% of revenues, respectively.

At March 31, 2026, CMS accounted for approximately 36% of accounts receivable. At December 31, 2025, CMS a U.S. commercial insurer and its affiliates, and an O&P customer, accounted for approximately 25% and 16%, and 12%, of accounts receivable, respectively.

For the three months ended March 31, 2026 and 2025, approximately 18% and 17% of the Company's revenues, respectively, were derived from patients with Medicare Advantage insurance plans.

------

**Note 12 — Subsequent Events**

The Company evaluated subsequent events through the date the financial statements issued and determined that there have been no subsequent events that would require recognition in the financial statements or disclosure in the notes to the unaudited condensed consolidated financial statements.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes contained elsewhere in this Quarterly Report on Form 10-Q and in our other Securities and Exchange Commission filings. The following discussion may contain predictions, estimates, and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under "Risk Factors", "Cautionary Statement Regarding Forward-Looking Statements" and elsewhere in this Quarterly Report on Form 10-Q and those described under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025. These risks could cause our actual results to differ materially from any future performance suggested below.*

***Overview*** 

We are a wearable medical robotics company, specializing in myoelectric braces, or orthotics, for people with neuromuscular disorders. We develop and market the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient's weak or deformed arm to enable and improve functional activities of daily living, ("ADLs") in the home and community. It is custom constructed by a trained professional during a custom fabrication process for each individual user to meet their specific needs. Our products are designed to help regain function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders.

We advertise on television and through social media. In addition, we perform in-services for therapists and physicians to generate referrals under a new program we refer to as MyoConnect, and we directly educate and inform those individuals who are potential candidates for our products. Once the prospective patient contacts us or is referred to us through our MyoConnect program, either our trained clinical staff or a trained O&P provider will evaluate the patient for their suitability as a candidate. Initial evaluations by our trained clinical staff are often initially conducted using telehealth techniques, followed by an in-person clinical evaluation of the candidate. Prior to obtaining authorizations from commercial insurance companies or delivering to a patient with Medicare Part B, the patient's medical records are collected and reviewed to make sure the device is medically necessary for their condition and a prescription is always obtained from a physician. Once these documents are obtained, if the patient has Medicare Advantage or other commercial insurance, a pre-authorization request is submitted to the patient's insurer. If we receive a pre-authorization, we proceed to measure the patient's arm, a process we call "shape capture". In many cases, shape capture is done using a remote measurement kit supplied to the patient. If the patient is covered by Medicare Part B, no pre-authorization is required, and we can move directly to taking measurements of the patient's arm. We then use those measurements to 3D print orthotic parts, which are used to fabricate the MyoPro, and then deliver it to the patient. Since we are directly providing the device to the patient and then billing insurance ourselves, we refer to this process as direct billing. We also call on hospitals and O&P practices in the United States, Europe and Australia that provide our products to their patients as well as generate indirect sales. The MyoPro product line has been approved by the VA system for impaired veterans, and over 130 VA facilities have ordered devices for their patients.

Our myoelectric orthoses have been clinically shown in peer reviewed published research studies to help regain the ability to complete functional tasks by supporting the affected joint and enabling individuals to self-initiate and control movement of their partially paralyzed limbs by using their own muscle signals. Our technology was originally developed at MIT in collaboration with medical experts affiliated with Harvard Medical School. Myomo was incorporated in 2004.

Other historical milestones include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In 2012, we introduced the MyoPro. The primary business focus shifted from developing devices that were designed for rehabilitation therapy and sold to hospitals to providing an assistive device through O&P providers to patients who are otherwise impaired for use at home, work, and in the community that facilitates ADLs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•During 2015, we extended our basic MyoPro for the elbow with the introduction of the MyoPro Motion W, a multi-articulated non-powered wrist and the MyoPro Motion G, which includes a powered grasp. The MyoPro Motion W allows the user to use their sound arm to adjust the device and then, for instance, open a refrigerator door, carry a shopping bag, hold a cell phone, or stabilize themselves to avoid a fall and potential injury. The MyoPro Motion G model allows users with severely weakened or clenched hands, such as seen in certain stroke survivors, to open and close their hands and perform a large number of ADLs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On June 9, 2017, we completed our initial public offering ("IPO") and a private offering concurrent with the IPO, generating net proceeds of $6.9 million in the aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On July 31, 2017, we met the criteria to apply the CE Mark for the MyoPro. This has enabled us to sell the MyoPro to individuals in the European Union (the "EU").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In November 2018, we announced that the Centers for Medicare and Medicaid Services ("CMS") had published two new codes (L8701, L8702) pursuant to our application for Healthcare Common Procedure Coding System ("HCPCS") codes which become effective in early 2019. The assignment of unique L-Codes, if followed by appropriate payment terms, should have the effect of offering greater access to the MyoPro for Medicare beneficiaries.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In 2019, we transitioned our business to become a direct provider of the MyoPro to patients and bill insurance companies directly.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In July 2021, we became accredited as a Medicare provider.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•In January 2022, we introduced MyoPro 2+ and began in-house fabrication of the device.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On November 1, 2023, CMS issued a final rule that resulted in a change in the benefit category associated with products billed under the HCPCS codes for our products from durable medical equipment rental to a brace, which would permit reimbursement of MyoPro sales on a lump sum basis. The rule became effective on January 1, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On February 29, 2024, CMS published final payment determinations for the HCPCS codes describing our products which are L8701, for the MyoPro Motion W, and L8702, for the MyoPro Motion G, which became effective on April 1, 2024. These fees were subsequently updated to approximately $34,970 for the Motion W and approximately $68,800 for the Motion G, effective January 1, 2026. These fees are subject to annual inflationary adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On April 30, 2025, we introduced an enhanced version of our flagship product, now known as the MyoPro 2x in the United States.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•On March 23, 2026, we introduced a mobile application to be used with the MyoPro, replacing the use of an external laptop.

***Recent Developments***

**Term Loan Facility**

On November 4, 2025 ("the Closing Date"), we entered into a Loan and Security Agreement with with Avenue Capital Management II, L.P., as administrative agent and collateral agent and Avenue Venture Opportunities Fund II, L.P., as a lender (together "Avenue"), which provides us $17.5 million in committed funding under two tranches. The first tranche of $12.5 million was funded on the Closing Date. The remaining $5.0 million becomes available at our discretion between 12 and 18 months from the Closing Date, subject to maintaining compliance with covenants. We are paying interest only on the term loan for a period of 18 months from the Closing Date, which could be extended to 24 months if we borrowed under the second tranche. After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments. The term loan matures on June 1, 2029. Proceeds from this loan were used to repay the outstanding borrowings under the credit facility with Silicon Valley Bank and to pay fees and expenses, with the remainder being used for general corporate purposes.

**China Joint Venture**

In November 2025, we were notified that Ryzur Medical filed for bankruptcy in China and is in the process of being liquidated. As a result, the operations of the JV Company are now severely limited. Chinaleaf Capital, a minority investor in the JV Company, is currently leading the process of restructuring the JV Company and raising additional capital in order to re-start normal operations. According to the terms of the JV Contract, the sale of shares in the JV Company will not dilute our ownership. We cannot provide any assurance that we will accept any terms and conditions that new investors, if any, will require and we may exercise our right to terminate the joint venture in the future.

All assets associated with our investment in the JV Company were either reserved or written off in prior periods. As a result, these events had no impact on our financial statements for the three months ended March 31, 2026 and the year ended December 31, 2025.

**Results of Operations**

We have been growing revenues while incurring net losses and negative cash flows from operations since inception and anticipate this to continue in 2026. Our financial performance in 2025 reflected our ability to be reimbursed by Medicare for providing the MyoPro to their beneficiaries, as well as challenges around marketing efficiency and patient acquisition which increased Cost Per Pipeline Add. Our plan for 2026 is to begin to pivot away from relying on direct to patient advertising to generate revenues and invest in generating revenues from recurring sources, including the MyoConnect referral program and from O&P providers in the U.S. and Germany, while implementing marketing initiatives to reduce Cost Per Pipeline Add in the direct billing channel and minimizing the growth of fixed expenses.

------

The following table sets forth our revenue, cost of revenue, gross profit and gross margin for each of the periods presented.

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** | **Period-<br>to-Period<br>Change** |
|  | **2026** | **2025** | $**%** |
| Revenue | $10113288 | $9831814 | 3% |
| Cost of revenue | 3211682 | 3222184 | (0)% |
| Gross profit | $6901606 | $6609630 | 4% |
| Gross margin % | 68.2% | 67.2% | 1.0% |

---

**<u>Revenues</u>**

We derive revenue primarily from providing devices directly to patients and billing insurance companies directly. We also sell our products to O&P providers in the U.S, Europe and Australia, to the VA, and to rehabilitation hospitals. Though we increasingly provide devices directly to patients, we sometimes utilize the clinical services of O&P providers for which they are paid a fee.

We expect that our revenues will continue to grow in 2026, primarily as a result of investments to grow revenues from recurring sources, including generating patient referrals under our MyoConnect program, as well as from O&P practices in the U.S. and Germany, which we expect to increase operating leverage and reduce our dependence on advertising-driven direct-to-patient revenues.

Total revenue increased by approximately $0.3 million, or 3%, for the three months ended March 31, 2026, as compared to the same period in 2025. The revenue increase was driven primarily by a higher average selling price ("ASP") as CMS provided an annual inflationary increase on its allowable, as well as a higher international revenue. Revenue by channel in the three months ending March 31, 2026 and 2025 are as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Direct billing | $7168477 | $7808777 |
| International | 2006862 | 1312766 |
| U.S. O&P | 842384 | 470720 |
| VA | 95565 | 239551 |
| Total revenue | $10113288 | $9831814 |

---

**<u>Cost of Revenue and Gross margin</u>**

Cost of revenue consists of direct costs for the manufacturing, casting/printing of orthotic parts, fabrication and fitting of our products, changes in inventory, warranty costs and overhead costs allocated to cost of revenue.

Gross margin was 68.2% for the three months ended March 31, 2026, compared to 67.2% for the three months ended March 31, 2025. The increase in gross margin was primarily due to a higher ASP and lower material costs, offset by higher clinical costs charged to cost of goods sold.

**<u>Operating expenses</u>**

The following table sets forth our operating expenses for each of the periods presented.

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** | **Period-to-Period<br>Change** |
|  | **2026** | **2025** | $**%** |
| Research and development | $1623160 | $1790024 | (9)% |
| Selling, clinical and marketing | 4816759 | 4395804 | 10% |
| General and administrative | 3618739 | 3944056 | (8)% |
| Total operating expenses | $10058658 | $10129884 | (1)% |

---

------

**Research and development**

**Res**earch and development ("R&D") expenses consist of costs for our engineering and R&D personnel, including salaries, benefits, bonuses and stock-based compensation, product development costs, clinical studies, and the cost of certain third-party contractors and travel expense. R&D costs are expensed as they are incurred. We intend to manage R&D expenses in 2026, while maintaining the pace of our R&D efforts as cash flows allow, as well as to fund a randomized control trial being conducted by the University of Utah.

R&D expenses decreased by approximately $0.2 million, or 9%, during the three months ended March 31, 2026, as compared to the same period in 2025. The decrease was primarily due to lower labor expense in project management, engineering, and research.

**Selling, clinical and marketing**

Selling, clinical, and marketing ("SC&M") expenses consist of costs for our business development, customer experience, field sales and clinical staff, clinical training organization, and marketing personnel, including salaries, benefits, bonuses, stock-based compensation and sales commissions, costs of advertising, marketing and promotional events, corporate communications, product marketing and travel expenses. Variable compensation for personnel engaged in sales and marketing activities is generally earned and recorded as expense when the product is delivered. We expect the growth rate in selling, clinical and marketing expenses to be lower in 2026. In addition to gaining leverage on our 2025 investments, we intend to make investments in our MyoConnect referral program, including clinical sales personnel, our international operations and support for the O&P channel, as we execute our strategy to reduce our dependence on advertising-driven direct billing revenues.

SC&M expenses increased by approximately $0.4 million or 10% during the three months ended March 31, 2026, as compared to the same period in 2025. The increase was primarily due to higher advertising expense and expenses associated with our new clinical sales personnel.

**General and administrative**

General and administrative ("G&A") expenses consist primarily of costs for administrative, reimbursement, and finance personnel, including salaries, benefits, bonuses and stock-based compensation, professional fees associated with legal matters, consulting expenses, costs for pursuing insurance reimbursements for our products and costs required to comply with the regulatory requirements of the SEC and Medicare accreditation, as well as costs associated with accounting systems, insurance premiums and other corporate expenses. We intend to reduce the growth rate in general and administrative expenses in 2026.

G&A decreased by approximately $0.3 million or 8%, during the three months ended March 31, 2026, as compared to the same period in 2025. The decrease was primarily due to a decrease in spending for outside consultants and professional fees.

**<u>Other (income), net</u>**

The following table sets forth our interest and other income, net for each of the periods presented:

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** | **Period-to-Period<br>Change** |
|  | **2026** | **2025** | **%** |
| Interest expense (income), net | $504696 | $(191991) | N/M |
| Change in fair value of derivatives liabilities | (839064) | -) | N/M |
| Total other income, net | $(334368) | $(191991) | 74% |

---

Other (income), net was income of approximately $334,400 for the three months ended March 31, 2026 compared to income of approximately $192,000 for the same period in 2025. The increase in other income, net was due to the change in fair value of derivative liabilities related to our term loan with Avenue, driven primarily by a decrease in our stock price and market volatility. This was offset higher interest expense due to our term loan with Avenue entered into in November 2025.

**<u>Income tax expense</u>**

Income tax expense recorded during the three months ended March 31, 2026 and 2025 represents the provision for income taxes for our wholly-owned subsidiary, Myomo Europe GmbH. Income tax expense increased in the three months ended March 31, 2026 as a result of higher taxable income compared to the same period in 2025.

------

**<u>Adjusted EBITDA</u>**

We believe that the presentation of Adjusted EBITDA, a non-GAAP financial measure, provides investors with additional information about our financial results. Adjusted EBITDA is an important supplemental measure used by our board of directors and management to evaluate our operating performance from period-to-period on a consistent basis and as a measure for planning and forecasting overall expectations and for evaluating actual results against such expectations.

We define Adjusted EBITDA as earnings before interest and other expense (income), taxes, depreciation and amortization adjusted for stock-based compensation.

Adjusted EBITDA is not in accordance with, or an alternative to, measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. As a non-GAAP measure, Adjusted EBITDA has limitations in that it does not reflect all of the amounts associated with our results of operations as determined in accordance with U.S. GAAP. In particular:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA does not reflect the amounts we paid in taxes or other components of our tax provision;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA does not include interest expense (income), net;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA does not include depreciation expense from fixed assets or amortization of leasehold improvements and software costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA does not include the impact of stock-based compensation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA does not include the impact of change in fair value of derivative liabilities.

Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures including net income (loss) and our financial results presented in accordance with U.S. GAAP.

The following table provides a reconciliation of net loss to Adjusted EBITDA for each of the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months<br>Ended March 31,** | **For the Three Months<br>Ended March 31,** |
|  | **2026** | **2025** |
| GAAP net loss | $(3009399) | $(3465058) |
| Adjustments to reconcile to Adjusted EBITDA: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense (income), net | 504696 | (191991) |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 291590 | 158442 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 597248 | 540204 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (839064) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 186715 | 136795 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $(2268214) | $(2821608) |

---

***<u>Liquidity and Capital Resources</u>***

***Liquidity***

We measure our liquidity in a number of ways, including the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Cash and cash equivalents | $11396426 | $14132027 |
| Short-term investments | 4299978 | 4261782 |
| Total | 15696404 | 18393809 |
| Working capital | $16272798 | $19211756 |

---

As of March 31, 2026, we had working capital of approximately $16.3 million and stockholders' equity of approximately $9.0 million. We used approximately $2.2 million in cash for operating activities during the three months ended March 31, 2026.

We have historically funded our operations through financing activities, including raising equity and debt capital. On November 4, 2025, we entered into a Loan and Security Agreement with Avenue, which provides us $17.5 million in committed funding under two tranches. The first

------

tranche of $12.5 million was funded on the Closing Date. The remaining $5.0 million becomes available at our discretion between 12 and 18 months from the Closing Date, subject to maintaining compliance with covenants. We are paying interest only on the term loan for a period of 18 months from the Closing Date, which could be extended to 24 months if we borrowed under the second tranche. After the expiration of the interest-only period, we will re-pay the principal balance in 24 equal monthly installments. The term loan matures on June 1, 2029. Proceeds from this loan were used to repay the outstanding borrowings under the credit facility with Silicon Valley Bank and to pay fees and expenses, with the remainder being used for general corporate purposes. Considering our cash balance, our debt service and our operating plans discussed below, we believe there will be sufficient cash to fund our operations and capital expenditures for the next 12 months from the date of this report.

Our operating plans are primarily focused on growing revenues from recurring sources, including expanding our MyoConnect program to generate referrals in rehab clinics and stroke centers around the country, continued growth in revenues in the U.S. O&P channel, as well as International operations, while reducing the cost of patient acquisition (measured as Cost Per Pipeline Add) in the direct billing channel and minimizing the growth in fixed expenses.

Our business is dependent upon reimbursement of our products by insurance companies and government-controlled health care plans such as Medicare and Medicaid in the United States and by statutory health insurance plans in Germany, which could prevent our revenues from growing to the level necessary to return to cash flow breakeven on a sustaining basis. We believe that we have access to capital resources, if necessary, through potential public or private equity offerings, debt financings, or other means. If we are unable to obtain adequate funds on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing agreements on unattractive terms. We may also explore strategic alternatives for the purpose of maximizing stockholder value. There can be no assurance we will be successful in implementing our plans to sustain our operations and continue to conduct our business.

***Cash Flows***

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net cash used in operating activities | $(2197336) | $(2676899) |
| Net cash used in investing activities | (494345) | (1896098) |
| Net cash used in financing activities | - | (36506) |
| Effect of foreign change rate changes on cash | (43920) | 30929 |
| Net (decrease) in cash, cash equivalents and restricted<br> cash | $(2735601) | $(4578574) |

---

*Operating Activities*. The net cash used in operating activities for the three months ended March 31, 2026 was primarily used to fund a net loss of approximately $3.0 million, adjusted for non-cash expenses in the aggregate amount of approximately $0.5 million use of cash and a source of approximately $0.3 million of cash by net changes in the levels of operating assets and liabilities, primarily related to decrease in prepaid expenses and other current assets and in accounts payable and accrued expenses, offset by an increase in accounts receivable.

The net cash used in operating activities for the three months ended March 31, 2025 was primarily used to fund a net loss of approximately $3.5 million, adjusted for non-cash expenses in the aggregate amount of approximately $1.0 million and by approximately $0.2 million of cash used by net changes in the levels of operating assets and liabilities, primarily related to increases in accounts receivable, inventory and prepaid expenses and other current assets, offset by an increase in accounts payable and accrued expenses.

*Investing Activities*. During the three months ended March 31, 2026 and 2025, our cash used in investing activities of approximately $0.5 million and $1.9 million, respectively, was primarily related to our purchase of short-term investments and purchases of equipment.

*Financing Activities*. Cash used by financing activities during the three months ended March 31, 2025, was due to payment of issuance costs associated with the amendment to our former line of credit agreement with Silicon Valley Bank.

**Critical Accounting Estimates**

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Materially different results can occur if circumstances change and additional information becomes known. Actual results may differ from these estimates. Refer to *Note 3 - Summary of Significant Accounting* 

------

*Policies.* Our most critical accounting estimates include the timing and amount of revenue recognition based on assertions, revenue recognition based on transaction pricing estimated from payments from certain insurance payers and valuation of derivative liabilities

***Timing and Amount of Revenue Recognition***

The timing and amount of revenue recognized is determined based on certain estimates. For revenue derived from patients with Medicare Part B, we determined we had sufficient payment history in order to recognize revenue upon delivery of the device to the patient based on the published fees by CMS. With respect to patients with Medicare Advantage or other commercial insurance, except for a small number of payers, we do not have contracts to establish pricing or provide evidence of an arrangement, however we are able to rely on a history of payments after receiving an insurance authorization, delivery of the device and submission of a claim as evidence of an arrangement. For these payers, payment history is also used to estimate how much we expect to be paid upon delivery of our device and submission of an insurance claim, which determines how much revenue we recognize. The transaction pricing for these providers is based on the expected value method, based on previous history. For the majority of Medicare Advantage and other commercial insurance payers, we have determined that we do not have sufficient collection history with the payer to assert evidence of an arrangement and collectability. For these payers, revenue is recognized at payment, which is when we can determine how much we will be paid for the device.

***Valuation of Derivative Liabilities***

Our derivative liabilities are recorded at fair value on the basis of both observable and unobservable inputs. With respect to the derivative liability for the warrant issued to Avenue, these inputs include our stock price, expected volatility of our stock price, remaining term of the warrant and assumptions around the probability of an equity financing resulting in an adjustment to the warrant exercise price. Our derivative liability for the compound derivative feature in the term loan with Avenue is based on similar assumptions, but also including the credit spread and remaining term of the debt.

**Recent Accounting Standards**

Information regarding new accounting standards is included in Note 3 — *Recently Adopted Accounting Standards* to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

This item is not applicable to us as a smaller reporting company.

**Item 4. Controls and Procedures**

***Evaluation of Disclosure Controls and Procedures***

The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer, our principal executive officer, and our Chief Financial Officer, our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026, the end of the period covered by this Quarterly Report on Form 10-Q.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2026, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of such date at the reasonable assurance level.

***Management's Report on Internal Control over Financial Reporting***

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

------

Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2026. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on our assessment, we believe that as of March 31, 2026, our internal control over financial reporting was effective at the reasonable assurance level.

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

**Part II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There is no material litigation against the Company at this time that is required to be disclosed under Item 103 of Regulation S-K.

**Item 1A. Risk Factors**

Except as set forth below, there have been no material changes to our risk factors from those disclosed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025.

***Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.***

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations and U.S. customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign Assets Control and the U.S. Department of State. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. While it has not had a material impact on our business to date, we sell our products in countries throughout the world and import materials into the United States. Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products are difficult to predict and may have a material adverse effect on us. These developments may include export controls, tariffs or changes in reimbursement policies for Medicaid and Medicare. For example, the U.S. has imposed tariffs on certain imports from China and other countries, and these tariffs may continue to escalate, depending on the status of trade negotiations. Historically, tariffs have led to increased trade and political tensions. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Though the United States has reached trade agreements with certain countries and the U.S. Supreme Court has struck down the legal basis for some of the implemented tariffs, significant uncertainty around future tariff policies remains. The United States is conducting investigations that could result in higher tariffs. While we estimate that tariffs assessed on our imports are expected to have less than a 100 basis point (1%) impact on gross margin in 2026, we cannot provide any assurance that the final tariffs actually imposed, changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, will not have a material adverse effect on our financial condition or results of operations.

***If we fail to properly manage our anticipated growth, including in O&P channel and international markets, our business could suffer.***

As we grow our revenues from Medicare Part B patients and expand the number of locations which provide the MyoPro products, including O&P practices in the United States, and future planned international distribution, we expect that it will place significant strain on our management team and on our financial resources. Failure to manage our growth effectively could cause us to mis-allocate management or financial resources and result in losses or weaknesses in our infrastructure, systems, processes and controls, which could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on our suppliers, resulting in an increased need for us to manage our suppliers and monitor for quality assurance.

Moreover, there are significant costs and risks inherent in selling our products, particularly in international markets, including: (a) time and difficulty in building a widespread network of distribution partners; (b) increased shipping and distribution costs, which could increase our expenses and reduce our margins; (c) potentially lower margins in some regions; (d) longer collection cycles in some regions; (e) compliance with foreign laws and regulations; (f) compliance with anti-bribery, anti-corruption, sanctions, export controls, import and customs, and anti-money laundering laws, such as the Foreign Corrupt Practices Act and the Office of Foreign Assets Control regulations, by us, our employees, and our business partners; (g) currency exchange rate fluctuations and related effects on our results of operations; (h) economic weakness, including inflation, or political instability in foreign economies and markets; (i) compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; (j) workforce uncertainty in countries where labor unrest is more common than in the United States; (k) business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters, including earthquakes, typhoons, floods and fires; and (l) other costs and risks of doing business internationally, such as new tariffs which may be imposed.These and other factors could harm our ability to implement planned growth in international operations and, consequently, harm our business, results of operations, and financial condition. Further, we may incur significant operating expenses as a result of our planned expansion activities, and they may not be successful. We have limited experience with regulatory environments and market practices internationally, and we may not be able to penetrate or successfully operate in new markets. We may also encounter difficulty growing the O&P channel while simultaneously being a direct provider to patients in the United States. and expanding into international markets because of limited brand recognition. These factors may lead to delayed or limited acceptance of our products by patients in these markets. Accordingly, if we are unable to expand O&P

------

channel revenues in the United States, expand internationally or manage our international operations successfully, we may not achieve the expected benefits of this expansion and our financial condition and results of operations could be harmed.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities**

None.

**Item 5. Other Information**

None.

------

**Item 6. Exhibits**

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibits Index, which is incorporated by reference.

**Exhibits Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 3.1 | [<u>Eighth Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 2.3 contained in the Registrant's Form 1-A filed on January 6, 2017)</u>](https://www.sec.gov/Archives/edgar/data/1369290/000121390017000146/f1a2016ex2iii_myomoinc.htm) |
| 3.2 | [<u>Amended and Restated Bylaws (Incorporated by reference to Exhibit 2.4 contained in the Registrant's Form 1-A filed on January 6, 2017)</u>](https://www.sec.gov/Archives/edgar/data/1369290/000121390017000146/f1a2016ex2iv_myomoinc.htm) |
| 3.3 | [<u>Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended, of Myomo, Inc., filed with the Secretary of the State of Delaware on January 30, 2020 (Incorporated by reference to Exhibit 3.1 contained in the Registrant's Form 8-K filed on January 30, 2020)</u>](https://www.sec.gov/Archives/edgar/data/1369290/000119312520019589/d881263dex31.htm) |
| 3.4 | [<u>Second certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation, as amended, of Myomo, Inc., filed with the Secretary of the State of Delaware on June 10, 2021 (Incorporated by reference to Exhibit 3.1 contained in the Registrant's Form 8-K filed on June 15, 2021)</u>](https://www.sec.gov/Archives/edgar/data/1369290/000119312521191197/d131818dex31.htm) |
| 31.1\* | [<u>Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) or 15(d)-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](myo-ex31_1.htm) |
| 31.2\* | [<u>Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) or 15(d)-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](myo-ex31_2.htm) |
| 32.1+ | [<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](myo-ex32_1.htm) |
| 32.2+ | [<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](myo-ex32_2.htm) |
| 101.INS\* | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document with embedded linkbase documents. |
| 104\* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

\* Filed herewith.

+ The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

------

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2026

---

| |
|:---|
| **Myomo, Inc**. |
| /s/ David A. Henry |
| David A. Henry |
| Chief Financial Officer<br>(Principal Financial and Accounting Officer) |

---

------

## Exhibit 31.1

**Exhibit 31.1**

**Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934**

I, Paul R. Gudonis, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Myomo, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ Paul R. Gudonis |
| Paul R. Gudonis |
| President and Chief Executive Officer<br>(Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**Certification Pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934**

I, David A. Henry, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Myomo, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ David A. Henry |
| David A. Henry |
| Chief Financial Officer<br>(Principal Financial Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

I, Paul R. Gudonis, President and Chief Executive Officer of Myomo, Inc. (the "Company"), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

(1) the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2026

---

| |
|:---|
| /s/ Paul R. Gudonis |
| Paul R. Gudonis |
| President and Chief Executive Officer<br>(Principal Executive Officer) |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

I, David A. Henry, Chief Financial Officer of Myomo, Inc. (the "Company"), certify, pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that:

(1) the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 780(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 7, 2026

---

| |
|:---|
| /s/ David A. Henry |
| David A. Henry |
| Chief Financial Officer<br>(Principal Financial Officer) |

---

------